IGC PHARMA INC (IGC) Stock Price, Forecast & Analysis
NYSEARCA:IGC • US45408X3089
IGC Key Statistics, Chart & Performance
The current stock price of IGC is 0.2602 USD. In the past month the price decreased by -13.58%. In the past year, price decreased by -12.09%.
IGC Technical Analysis
IGC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to IGC. Both the profitability and financial health of IGC have multiple concerns.
IGC Financial Highlights
Over the last trailing twelve months IGC reported a non-GAAP Earnings per Share(EPS) of -0.08. The EPS increased by 58.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -66.16% | ||
| ROE | -79.66% | ||
| Debt/Equity | 0.02 |
IGC Forecast & Estimates
5 analysts have analysed IGC and the average price target is 3.7 USD. This implies a price increase of 1321.02% is expected in the next year compared to the current price of 0.2602.
For the next year, analysts expect an EPS growth of 30.18% and a revenue growth 4.61% for IGC
IGC Ownership
IGC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.08 | 967.332B | ||
| JNJ | JOHNSON & JOHNSON | 20.81 | 594.88B | ||
| MRK | MERCK & CO. INC. | 22.6 | 302.459B | ||
| PFE | PFIZER INC | 8.87 | 152.718B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.97 | 122.756B | ||
| ZTS | ZOETIS INC | 18.75 | 56.091B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.7 | 26.039B | ||
| VTRS | VIATRIS INC | 6.29 | 18.405B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.89 | 12.521B | ||
| AXSM | AXSOME THERAPEUTICS INC | 224.33 | 9.385B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IGC
Company Profile
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. The company is headquartered in Potomac, Maryland and currently employs 70 full-time employees. The company went IPO on 2006-04-13. The firm's lead asset, IGC-AD1, is a cannabinoid-based therapy is in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. The Company’s pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. The firm integrates AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. The company is also developing a Multimodal Interpretable Transformer for Alzheimer’s Disease (MINT-AD). MINT-AD leverages diverse data sources, including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories.
Company Info
IGC PHARMA INC
10224 Falls Road
Potomac MARYLAND 20854 US
CEO: Ram Mukunda
Employees: 70
Phone: 13015294996
IGC PHARMA INC / IGC FAQ
What does IGC do?
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. The company is headquartered in Potomac, Maryland and currently employs 70 full-time employees. The company went IPO on 2006-04-13. The firm's lead asset, IGC-AD1, is a cannabinoid-based therapy is in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. The Company’s pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. The firm integrates AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. The company is also developing a Multimodal Interpretable Transformer for Alzheimer’s Disease (MINT-AD). MINT-AD leverages diverse data sources, including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories.
What is the stock price of IGC PHARMA INC today?
The current stock price of IGC is 0.2602 USD. The price decreased by -0.04% in the last trading session.
Does IGC PHARMA INC pay dividends?
IGC does not pay a dividend.
What is the ChartMill technical and fundamental rating of IGC stock?
IGC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
On which exchange is IGC stock listed?
IGC stock is listed on the NYSE Arca exchange.
What do analysts say about IGC PHARMA INC (IGC) stock?
5 analysts have analysed IGC and the average price target is 3.7 USD. This implies a price increase of 1321.02% is expected in the next year compared to the current price of 0.2602.
What is the Price/Earnings (PE) ratio of IGC PHARMA INC (IGC)?
IGC PHARMA INC (IGC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.08).